Valeria Giandomenico
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Valeria Giandomenico has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Kjell Öberg
Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
2 shared publicationsMagnus Essand
Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
2 shared publicationsAhmed Essaghir
Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
1 shared publicationC Hellberg
Ludwig Institute for Cancer Research, Uppsala, Sweden 4
1 shared publicationGeorge Vasmatzis
Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
1 shared publicationJ Grawé
Department of Genetics and Pathology, 2
1 shared publication
Latest Publications
- 1 February 2009
- Published by Elsevier in Laboratory Investigation
- Vol. 22 (2) , 261-272
Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas
- 1 February 2009
- Published by Elsevier in Laboratory Investigation
- Vol. 22 (2) , 261-272
Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas
- Open Access
- 1 December 2005
- Published by Bioscientifica in Journal of Molecular Endocrinology
- Vol. 35 (3) , 489-501
Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1
Vesicular monoamine transporter 1 (VMAT1) is an integral protein in the membrane of secretory vesicles of neuroendocrine and endocrine cells that allows the transport of biogenic monoamines, such as serotonin, from the cytoplasm into the secretory vesicles. The full-length VMAT1 transcript is produced from 16 exons. We have identified and characterized an alternatively spliced form of VMAT1 that lacks exon 15, the next to last exon of VMAT1. The new form was therefore denoted VMAT1Δ15. Exon 15 does not contain an even multiple of three nucleotides. As a consequence, there is a shift of reading frame, and exon 16 is translated in an alternative reading frame, yielding a novel protein with a shorter and unrelated C-terminus compared with the native VMAT1 protein. VMAT1 and VMAT1Δ15 mRNAs are simultaneously expressed in normal and neoplastic neuroendocrine cells of the GI tract. However, VMAT1 expression is always higher than VMAT1Δ15 expression. We prove that VMAT1Δ15 is not localized in large, dense core vesicles as the native form but in the endoplasmic reticulum. Furthermore, while VMAT1 can take up serotonin, VMAT1Δ15 cannot, indicating different functions for the two forms of VMAT1.
- 1 December 2005
- Published by Bioscientifica in Journal of Molecular Endocrinology
- Vol. 35 (3) , 489-501
Open AccessIdentification and characterization of a novel splicing variant of vesicular monoamine transporter 1
Vesicular monoamine transporter 1 (VMAT1) is an integral protein in the membrane of secretory vesicles of neuroendocrine and endocrine cells that allows the transport of biogenic monoamines, such as serotonin, from the cytoplasm into the secretory vesicles. The full-length VMAT1 transcript is produced from 16 exons. We have identified and characterized an alternatively spliced form of VMAT1 that lacks exon 15, the next to last exon of VMAT1. The new form was therefore denoted VMAT1Δ15. Exon 15 does not contain an even multiple of three nucleotides. As a consequence, there is a shift of reading frame, and exon 16 is translated in an alternative reading frame, yielding a novel protein with a shorter and unrelated C-terminus compared with the native VMAT1 protein. VMAT1 and VMAT1Δ15 mRNAs are simultaneously expressed in normal and neoplastic neuroendocrine cells of the GI tract. However, VMAT1 expression is always higher than VMAT1Δ15 expression. We prove that VMAT1Δ15 is not localized in large, dense core vesicles as the native form but in the endoplasmic reticulum. Furthermore, while VMAT1 can take up serotonin, VMAT1Δ15 cannot, indicating different functions for the two forms of VMAT1.
- Open Access
- 1 February 2005
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 44 (1) , 32-40
Gene expression in midgut carcinoid tumors: Potential targets for immunotherapy
Classical midgut carcinoids are serotonin-secreting tumors derived from enterochromaffin cells in the gut. Metastatic disease represents a therapeutic challenge and immunotherapy implies a novel approach for treatment. In order to define antigens suitable for T-cell therapy with a preferential expression in midgut carcinoid tissue a broad screening of genes with preferential neuroendocrine restriction, genes described as over-expressed in various malignancies, and genes encoding cancer-testis associated antigens was performed. The expression of 32 genes was analyzed by reverse transcription polymerase chain reaction (RT-PCR) in 28 midgut carcinoid specimens, in the cell line BON and in normal tissues. Immunohistochemistry (IHC) was used to evaluate protein expression. Expression is shown of genes that have previously not been observed in midgut carcinoid tumors, such as Survivin and GAGEs. Also the expression is confirmed of genes that encode pivotal proteins in enterochromaffin cells, such as TPH1 and VMAT1, and their tissue-restricted expression is indicated. In addition, gene expression of IA-2 and CDX-2 in normal gastrointestinal (GI) tract and in tumor is shown. Protein expression of TPH, VMAT1, and Survivin was detected in tumor tissue. This study elucidates that TPH1, VMAT1, and Survivin should be further investigated as potential target antigens for T cell-mediated immunotherapy of midgut carcinoids.
- 1 February 2005
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 44 (1) , 32-40
Open AccessGene expression in midgut carcinoid tumors: Potential targets for immunotherapy
Classical midgut carcinoids are serotonin-secreting tumors derived from enterochromaffin cells in the gut. Metastatic disease represents a therapeutic challenge and immunotherapy implies a novel approach for treatment. In order to define antigens suitable for T-cell therapy with a preferential expression in midgut carcinoid tissue a broad screening of genes with preferential neuroendocrine restriction, genes described as over-expressed in various malignancies, and genes encoding cancer-testis associated antigens was performed. The expression of 32 genes was analyzed by reverse transcription polymerase chain reaction (RT-PCR) in 28 midgut carcinoid specimens, in the cell line BON and in normal tissues. Immunohistochemistry (IHC) was used to evaluate protein expression. Expression is shown of genes that have previously not been observed in midgut carcinoid tumors, such as Survivin and GAGEs. Also the expression is confirmed of genes that encode pivotal proteins in enterochromaffin cells, such as TPH1 and VMAT1, and their tissue-restricted expression is indicated. In addition, gene expression of IA-2 and CDX-2 in normal gastrointestinal (GI) tract and in tumor is shown. Protein expression of TPH, VMAT1, and Survivin was detected in tumor tissue. This study elucidates that TPH1, VMAT1, and Survivin should be further investigated as potential target antigens for T cell-mediated immunotherapy of midgut carcinoids.